ArticleFrontiers in medicine2026
Analytical validation of capillary blood Krebs von den Lungen-6 measurement using a high- sensitivity chemiluminescent immunoassay in pediatric patients.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study evaluates the analytical validity of capillary blood for Krebs von den Lungen-6 (KL-6) detection using a high-sensitivity chemiluminescent immunoassay (CLIA) on the C5000 analyser and assesses agreement between capillary plasma and venous plasma measurements, with emphasis on methodological feasibility rather than clinical diagnostic performance. Methods: Analytical performance was assessed in terms of repeatability, accuracy and method comparison. Precision was evaluated using pediatric venous plasma samples at three concentration levels, each tested in 20 replicates. Accuracy was verified using manufacturer standards and external quality controls. Comparative analysis involved 80 paired venous plasma and capillary blood samples, with hematocrit (HCT)-based correction applied to address dilutional effects. Agreement between venous and capillary plasma measurements was evaluated using Passing-Bablok regression, Pearson correlation and Bland-Altman analysis. Pediatric and adult KL-6 levels were also profiled to evaluate age-specific differences. Results: The C5000 analyzer demonstrated excellent repeatability, with coefficients of variation below 3% across all concentration levels. Accuracy assessment showed minimal bias relative to the standards and controls. Passing-Bablok regression indicated proportional bias before HCT correction, with a slope of 0.769 (95% CI, 0.550-0.945). After correction, the slope was 1.004 (95% CI, 0.882-1.162) and the intercept was -7.03 U/mL (95% CI, -26.97 to 9.76). The mean capillary-minus-venous bias decreased from -48.32 to -3.47 U/mL, and the Pearson correlation coefficient increased from 0.958 to 0.966. Pediatric KL-6 levels were significantly lower than adult levels ( Conclusion: High-sensitivity CLIA on the C5000 analyzer supports the analytical feasibility of KL-6 measurement in pediatric capillary blood. HCT correction improved agreement with venous plasma measurements, although further validation is required before the two sample types can be considered interchangeable for individual clinical assessment and before formal reference intervals can be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.